One week after reporting outsized interim data on the phase I/II study of BMN 270 – potentially giving the company the inside track in hemophilia A – Biomarin Pharmaceutical Inc. cruised to record quarterly and first-half revenues of $300.1 million and $536.9 million, respectively.